• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

4.260 -0.300 (-6.58%)
Official Closing Price Updated: 8:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 Next >
News headline image
CEL-SCI Reports Fiscal First Quarter 2026 Results
February 18, 2026
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal 2025 Results
December 29, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $10 Million Public Offering
August 29, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $10 Million Public Offering
August 27, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Proposed Public Offering
August 27, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
August 14, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
August 13, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
July 14, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
July 11, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
July 11, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
June 18, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of Public Offering
May 23, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of Public Offering
May 21, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Proposed Public Offering
May 21, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
May 21, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Combination of Common Stock
May 19, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
May 15, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
April 23, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
April 08, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
March 24, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $2.5 Million Offering
March 18, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $2.5 Million Offering
March 17, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
March 17, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
March 14, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
February 20, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
February 18, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
January 14, 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $5 Million Offering
December 31, 2024
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $5 Million Public Offering
December 29, 2024
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Proposed Public Offering of Common Stock
December 27, 2024
From CEL-SCI Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap